Dutch biotech raises €30M for upscaled manufacturing, pilot study of blood clotting drug
VarmX, a Dutch biotech developing a reversal agent for blood thinners, has bagged a €30 million Series B2 round as it gets ready to launch …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
